Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising.
Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its precision oncology strategy through ONC010, a nanoparticle-encapsulated PNKP inhibitor being developed for biomarker-selected cancers. The company is building the manufacturing and scientific foundation needed to advance the program toward first-in-human studies, including polymer process development and analytical characterization activities with Nanosoft Polymers and metabolism studies through Nucro-Technics as part of its IND-enabling program. These efforts are designed to support scalable manufacturing, characterize ONC010’s metabolic profile and generate data for future pharmacokinetic, toxicology and regulatory activities. By combining targeted PNKP inhibition, nanoparticle drug delivery and AI-driven discovery capabilities, Onco-Innovations is positioning its development platform to pursue therapies for cancers that may be particularly susceptible to DNA damage response approaches as precision medicine continues to expand.
To view the full article, visit https://nnw.fm/5xv3t
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. For more information, visit the company’s website at https://oncoinnovations.com/.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://nnw.fm/ONNVF
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
